key: cord-0843650-i8rb5k2u authors: Tomasoni, Daniela; Adamo, Marianna; Metra, Marco title: December 2020 at a glance: focus on COVID‐19, comorbidities and palliative care date: 2021-02-08 journal: Eur J Heart Fail DOI: 10.1002/ejhf.1527 sha: beafab8d2a154633eac945a9d0de8e6554212d7d doc_id: 843650 cord_uid: i8rb5k2u nan The coronavirus disease 2019 (COVID-19) pandemic had a catastrophic impact on health systems worldwide. In Germany, hospitalizations due to acute heart failure (HF) had a reduction in the first pandemic period (13) (14) (15) (16) (17) (18) (19) (20) (21) May 2020) compared to control intervals in 2020 (1 January-12 March) and 2019 (13) (14) (15) (16) (17) (18) (19) (20) (21) , with an increase in case severity and in-hospital mortality. 1 Similarly, a study conducted in London showed a reduction in HF hospitalizations during the pandemic period, compared to the previous year. Although patients had similar characteristics to those of the patients hospitalized in 2019, in-hospital mortality was significantly higher in 2020 than in 2019 (P = 0.015) and hospitalization in 2020 was independently associated with increased in-hospital mortality. 2 In a study conducted in Madrid, Spain, including 3080 COVID-19 patients, those with a previous history of chronic HF were more likely to develop acute HF (11.2% vs. 2.1%; P < 0.001) and had higher mortality rates (48.7% vs. 19.0%; P < 0.001). 3 In an Italian study including 13 centres and 692 patients, history of HF was an independent predictor of increased in-hospital mortality [adjusted hazard ratio (HR) 2.25, 95% confidence interval (CI) 1.26-4.02; P = 0.006), along with age, sex, oxygen saturation and oxygen partial pressure/fraction of inspired oxygen (PaO 2 /FiO 2 ) ratio. 4 Concerns were raised that angiotensin-converting enzyme inhibitors (ACEi) or angiotensin II receptor blockers (ARBs) may enhance the susceptibility to COVID-19 through an increased expression of ACE2. 5 Lebek et al. 6 measured ACE2 mRNA expression using real-time quantitative polymerase chain reaction in atrial biopsies of 81 patients undergoing coronary artery bypass grafting. ACE2 mRNA expression was higher in patients treated with ACEi/ARBs compared to those not treated. Furthermore, ACEi/ARB treatment was associated with an independent increase in ACE2 expression in ventricle biopsies of patients with end-stage HF, while left ventricular (LV) assist device implantation led to a decline in mRNA expression. Although these data may show that ACE2 expression is increased by ACEi/ARB treatment, they do not imply that this may increase susceptibility to COVID-19 as ACE2 may actually have a protective role after infection has developed. 5 . A reduction of cardiac remodelling may be a therapeutic goal in HF with preserved ejection fraction (HFpEF). 7 Yamanaka et al. 8 investigated the prognostic impact of LV structural changes in patients with HFpEF from the Chronic Heart Failure Analysis and Registry in the Tohoku District-2 (CHART-2) study. Patients who presented LV hypertrophy and enlargement at baseline and those with LV hypertrophy who developed LV enlargement had a worse subsequent prognosis (HR 4.65, 95% CI 3.09-6.99, P < 0.001; HR 4.01, 95% CI 2.85-5.65, P < 0.001, respectively), compared with those without LV hypertrophy and enlargement. Cancer and HF have a close and complex relationship. 9,10 Common mechanistic pathways in cancer and HF, including inflammation, cellular metabolic changes, genetic predisposition, clonal haematopoiesis, angiogenesis, are summarized in this issue of the journal. 11 Cooperation between cardiologists and oncologists is key to manage properly these patients. 12 Zamorano et al. 13 provided an overview of the main cardiovascular adverse events of cancer therapy and proposed strategies for risk assessment, prevention, early diagnosis, medical management and long-term follow-up of cardiotoxicity. Frailty is frequent among HF patients and is associated with poor outcome. 14,15 Available knowledge of cachexia, muscle wasting and physical frailty in patients with cardiovascular illness is reviewed by Bielecka-Dabrowa et al. 16 Cardiac resynchronization therapy (CRT) in HF with reduced ejection fraction (HFrEF) is less used than indicated by guidelines and several studies tried to identify patients with major benefits from CRT. [21] [22] [23] A position statement in this issue is aimed at overcoming CRT under-utilization, improving patient selection and implementing dedicated post-implant CRT care pathways. 24 Kristensen et al. 25 studied the prognostic role of intra-ventricular conduction delay in HFrEF patients without a cardiac device enrolled in two recent major clinical trials. They found that a wide QRS was associated with an increased risk of the primary composite outcome of cardiovascular death or HF hospitalization, irrespective of morphology. New-onset left bundle branch block occurred with an incidence of about 2.5% per year, leading to a greater risk of adverse outcomes. Helios Hospitals, Germany. In-hospital care in acute heart failure during the COVID-19 pandemic: insights from the German-wide Helios hospital network Temporal trends in decompensated heart failure and outcomes during COVID-19: a multisite report from heart failure referral centres in London Heart failure in COVID-19 patients: prevalence, incidence and prognostic implications Impact of heart failure on the clinical course and outcomes of patients hospitalized for COVID-19. Results of the Cardio-COVID-Italy multicentre study COVID-19 and heart failure: from infection to inflammation and angiotensin II stimulation. Searching for evidence from a new disease Angiotensin-converting enzyme inhibitor/angiotensin II receptor blocker treatment and haemodynamic factors are associated with increased cardiac mRNA expression of angiotensin-converting enzyme 2 in patients with cardiovascular disease Long-term effects of Na+/Ca2+ exchanger inhibition with ORM-11035 improves cardiac function and remodelling without lowering blood pressure in a model of heart failure with preserved ejection fraction CHART-2 Investigators. Prognostic impacts of dynamic cardiac structural changes in heart failure patients with preserved left ventricular ejection fraction Cancer and heart failure-more than meets the eye: common risk factors and co-morbidities Heart Failure Association Cardio-Oncology Study Group of the European Society of Cardiology. Cancer diagnosis in patients with heart failure: epidemiology, clinical implications and gaps in knowledge Common mechanistic pathways in cancer and heart failure. A scientific roadmap on behalf of the Translational Research Committee of the Heart Failure Association (HFA) of the European Society of Cardiology (ESC) Activity and outcomes of a cardio-oncology service in the United Kingdom -a five-year experience The cancer patient and cardiology Heart Failure Association/European Society of Cardiology position paper on frailty in patients with heart failure The frailty syndrome and outcomes in the TOPCAT trial muscle wasting, and frailty in cardiovascular disease Which patients with heart failure should receive specialist palliative care? Advanced heart failure: a position statement of the Heart Failure Association of the European Society of Cardiology The impact of palliative care on clinical and patient-centred outcomes in patients with advanced heart failure: a systematic review of randomized controlled trials Effect of expanding evidence and evolving clinical guidelines on the prevalence of indication for cardiac resynchronization therapy in patients with heart failure CRT Survey II: a European Society of Cardiology survey of cardiac resynchronisation therapy in 11 088 patients -who is doing what to whom and how? Machine learning-based phenogrouping in heart failure to identify responders to cardiac resynchronization therapy Optimized Implementation of cardiac resynchronization therapy -a call for action for referral and optimization of care PARADIGM-HF and ATMOSPHERE Committees and Investigators. Prevalence and incidence of intra-ventricular conduction delays and outcomes in patients with heart failure and reduced ejection fraction: insights from PARADIGM-HF and ATMOSPHERE